{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:15:10Z","timestamp":1788970510223,"version":"build-2803163510"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>To identify time-specific factors associated with loss to follow-up (LTFU) in the early to medium term after initiating anti-vascular endothelial growth factor (VEGF) treatment in patients with neovascular age-related macular degeneration (nAMD) in Japan.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The study had a retrospective multicenter case\u2013control design and was performed across 16 specialist retinal facilities in Japan. Patients diagnosed with nAMD at their initial visit who initiated treatment between January 2017 and December 2020 were included. Patient characteristics were analyzed to identify factors associated with LTFU within 3 months (very early), 3 months to 1 year (early), and 1 year to 2 years (medium term) after starting treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Data for 2389 patients with nAMD were analyzed. The very early, early, and medium-term LTFU rates were 6.8%, 13.8%, and 21.2%, respectively. Stepwise regression analysis identified factors that were significantly associated with LTFU at a very early stage to be greater central retinal thickness at baseline and a prior treatment history, those associated with early LTFU to be worse baseline best-corrected visual acuity (BCVA), anti-VEGF treatment combined with photodynamic therapy, and a follow-up period that overlapped with the COVID-19 pandemic, and that associated with medium-term LTFU to be worse BCVA at 3 months. LTFU in any period within 3 months to 2 years was more likely in patients aged &gt;80 years, and LTFU very early within 3 months was more likely in those aged &lt;60 years. A poor baseline BCVA (logMAR) of &gt;1 was a risk factor for LTFU within 3 months and 1 year, whereas LTFU was significantly less likely in patients with good baseline BCVA (&lt;0.1).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The LTFU rate in patients with nAMD increased over time. Factors contributing to LTFU vary depending on the time since initiation of treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0325963","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T17:40:08Z","timestamp":1749663608000},"page":"e0325963","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Factors that contribute to loss to follow-up in the medium term after initiation of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in Japanese patients"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4679-8316","authenticated-orcid":true,"given":"Takaaki","family":"Sugisawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0807-8817","authenticated-orcid":true,"given":"Fumi","family":"Gomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofusa","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nagasato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Haruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9913-1905","authenticated-orcid":true,"given":"Tsutomu","family":"Yasukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Terasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Iesato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tsujinaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Mitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Wakuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5456-6374","authenticated-orcid":true,"given":"Masahiko","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the J-CREST (Japan Clinical Retina Study) Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"pone.0325963.ref001","doi-asserted-by":"crossref","first-page":"483034","DOI":"10.1155\/2012\/483034","article-title":"Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians","volume":"2012","author":"PA Keane","year":"2012","journal-title":"J Ophthalmol"},{"key":"pone.0325963.ref002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2017.12.019","article-title":"Evolution of Intravitreal Therapy for Retinal Diseases-From CMV to CNV: The LXXIV Edward Jackson Memorial Lecture","volume":"191","author":"DF Martin","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"pone.0325963.ref003","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1007\/s00417-021-05293-y","article-title":"Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study","volume":"259","author":"M Ohji","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"pone.0325963.ref004","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00417-016-3507-7","article-title":"A modified treat-and-extend regimen of aflibercept for treatment-na\u00efve patients with neovascular age-related macular degeneration","volume":"255","author":"M Ohnaka","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"pone.0325963.ref005","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jamaophthalmol.2019.4577","article-title":"Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial","volume":"138","author":"MS Ramakrishnan","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"pone.0325963.ref006","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.oret.2019.07.010","article-title":"Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor","volume":"4","author":"RR Soares","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"7","key":"pone.0325963.ref007","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ophtha.2023.02.021","article-title":"Loss to Follow-up in Patients with Neovascular Age-Related Macular Degeneration Treated with Anti-VEGF Therapy in the United States in the IRIS\u00ae Registry","volume":"130","author":"RN Khurana","year":"2023","journal-title":"Ophthalmology"},{"issue":"11","key":"pone.0325963.ref008","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jamaophthalmol.2018.3578","article-title":"Loss to Follow-up Among Patients With Neovascular Age-Related Macular Degeneration Who Received Intravitreal Anti-Vascular Endothelial Growth Factor Injections","volume":"136","author":"A Obeid","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"pone.0325963.ref009","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1097\/IAE.0000000000000526","article-title":"INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study","volume":"35","author":"F Gomi","year":"2015","journal-title":"Retina"},{"issue":"7","key":"pone.0325963.ref010","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial","volume":"136","author":"WK Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"pone.0325963.ref011","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial","volume":"138","author":"TH Lim","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"pone.0325963.ref012","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10384-023-00981-0","article-title":"Subtype prevalence and baseline visual acuity by age in Japanese patients with neovascular age-related macular degeneration","volume":"67","author":"T Sawada","year":"2023","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"pone.0325963.ref013","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","article-title":"Clinical characteristics of exudative age-related macular degeneration in Japanese patients","volume":"144","author":"I Maruko","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"pone.0325963.ref014","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-022-02593-7","article-title":"Long-term persistence with aflibercept therapy among treatment-na\u00efve patients with exudative age-related macular degeneration in a universal health care system: a retrospective study","volume":"22","author":"R Angermann","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"pone.0325963.ref015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ajo.2022.06.005","article-title":"Anti-Vascular Endothelial Growth Factor Treatment Discontinuation and Interval in Neovascular Age-Related Macular Degeneration in the United States","volume":"242","author":"SJ Bakri","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"pone.0325963.ref016","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00417-020-04703-x","article-title":"Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic","volume":"258","author":"J-F Korobelnik","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"pone.0325963.ref017","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/s41433-020-0925-x","article-title":"Current safety preferences for intravitreal injection during COVID-19 pandemic","volume":"34","author":"O Shmueli","year":"2020","journal-title":"Eye (Lond)"},{"issue":"7","key":"pone.0325963.ref018","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00417-020-04693-w","article-title":"Treating neovascular age-related macular degeneration in the era of COVID-19","volume":"258","author":"F Antaki","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"pone.0325963.ref019","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.oret.2020.05.015","article-title":"Management of Neovascular Age-Related Macular Degeneration during the COVID-19 Pandemic","volume":"4","author":"G Corradetti","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"pone.0325963.ref020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129361","article-title":"Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration","volume":"10","author":"R Gohil","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"pone.0325963.ref021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2015.06.023","article-title":"Disease Burden in the Treatment of Age-Related Macular Degeneration: Findings From a Time-and-Motion Study","volume":"160","author":"JL Prenner","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"14","key":"pone.0325963.ref022","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.3390\/jcm10143106","article-title":"Factors of Anti-Vascular Endothelial Growth Factor Therapy Withdrawal in Patients with Neovascular Age-Related Macular Degeneration: Implications for Improving Patient Adherence","volume":"10","author":"F Gomi","year":"2021","journal-title":"J Clin Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325963","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T17:40:14Z","timestamp":1749663614000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325963"}},"subtitle":[],"editor":[{"given":"Daniel Duck-Jin","family":"Hwang,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0325963","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]}}}